SKP2:FOXA1 ratios assess the intensity values for SKP2 and FOXA1 in relation to each other and in relevance to the stage of PCa, thus providing a potential biomarker for predicting PCa progression and positive treatment responses to SKP2 therapy. The gene discussed is FOXA1; the disease is posterior cortical atrophy.